Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammation and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NF-κB p65/RELA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (RHD Domain) | RELA (p65) RHD Domain (1-305 aa) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View RELA Products |
| Antigen (Full-Length Mutant) | RELA Phospho-Mimetic (S276D) & Null (S276A) Mutants Theoretical MW verified. For mechanism-specific inhibitor screening. |
View RELA Products |
| Heterodimer Complex | RELA:p50 Heterodimer (Pre-formed) For DNA-binding EMSA/AlphaScreen assays. High purity complex. |
View RELA Products |
| Gene Delivery | RELA Promise-ORF Lentivirus & NF-κB Reporter Lentivirus For stable cell line construction and pathway analysis. |
View RELA Products |
| Benchmark Ab | Anti-RELA (p65) Total & Phospho-Ser276 Recombinant positive controls for Western/IP. Sequence Verified. |
View RELA Products |
| Validator | RELA siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View RELA Products |
| Upstream Kinase | IKKβ (IKBKB) Critical upstream activator; kinase assay standard. |
View IKKβ Products |
| Heterodimer Partner | NFKB1 (p50) Essential binding partner for functional p65:p50 complex. |
View NFKB1 Products |
| Negative Regulator | IκBα (NFKBIA) Cytoplasmic sequestration protein; release assay standard. |
View IκBα Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Rel Family Selectivity (RELA vs c-Rel vs RelB) | Rel Homology Domain (RHD) proteins strictly verified by mass spec; >98% sequence purity for cross-screening. |
| Phospho-Specific Activation Status | S276 Phospho-mimetic (S276D) and Null (S276A) mutants available; Native glycosylation preserved in HEK293 system. |
| Heterodimer Formation (p65:p50) | Pre-formed RELA:p50 complex supplied at defined stoichiometry; Endotoxin controlled for cell-based DNA-binding assays. |
| Nuclear Translocation Validation | Lentivirus packaging system for stable reporter cell lines; preserve native conformation for microscopy/Flow assays. |
| Protein Stability in vitro | High Purity (>95%), rigorously quality-controlled recombinant proteins |
| Complex Formation Validation | Native conformation preserved for p50/p65 heterodimerization assays |
| Lack of Controls | Benchmark Antibodies included for reliable Western/ELISA |
| False Positives | Validated siRNA included for specificity checks |
Live RELA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NF-κB p65/RELA therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum inhibitors to targeted Small Molecules, PROTACs, and selective dimer disruption strategies. As first-generation therapies face toxicity limitations, the next wave of R&D is targeting direct protein degradation (PROTACs), highly specific dimerization inhibitors, and cell-permeable peptide inhibitors to overcome systemic toxicity and achieve pathway-specific modulation.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC Degraders | Arvinas, C4 Therapeutics; Early Stage Biotechs | Solid Tumors, Inflammation | Full-length RELA protein with native post-translational modifications; Phospho-Ser276 detection antibodies for degradation confirmation; Ternary complex validation. |
| Small Molecule (DNA-binding) | GlaxoSmithKline, Bayer; Academic Spin-offs | Autoimmune Diseases, Inflammatory Diseases | RELA RHD Domain for EMSA/AlphaScreen; Pre-formed p65:p50 heterodimer for competition assays; Binding/Inhibition assays. |
| Peptide Inhibitors | Academic Consortia | Chronic Inflammation | Mutant RELA proteins (dimerization-deficient) as specificity controls; High-concentration stability proteins for crystallography. |
| Decoy Oligonucleotides | Regulus Therapeutics | NF-κB Driven Cancers | RELA-dependent luciferase reporter lentivirus for functional validation. |
| Gene Therapy | Emerging Pharma | Severe Autoimmune | Cell-based Reporter Assays (Need Stable Cell Lines). |